Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Uroplasty Inc.
NEW YORK, June 14, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Uroplasty Inc. ("Uroplasty" or the "Company") (NasdaqCM: UPI). The investigation focuses on whether the Company and its executives violated federal securities laws.
On June 14, 2013, shares of Uroplasty fell 28 cents, or 11.3 percent, to $2.20 in morning trading after the company announced in a regulatory filing that it is delaying the filing of its latest annual report. The Company also announced that it has placed its chief financial officer on administrative leave because of problems with the company's recognition of orders and sales commission payments.
If you are aware of any facts relating to this investigation, or purchased shares of Uroplasty Inc. you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC